Hyderabad-based Suven Life Sciences announced today that two of its new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases were granted patents in Australia and New Zealand. The patents are valid up to 2022.The granted claims of these patents include the class of selective 5-HT compounds discovered by the company. These compounds are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer's, attention deficient hyperactivity, Huntington's, Parkinson and Schizophrenia, according to a release issued by the company today.Suven Life has, till now, filed 25 product patents under the patent co-operation treaty (PCT) of which 10 have entered the national phase. These are the first product patents granted to Suven Life from its four years of drugs discovery efforts. The company has already filed its first investigational new drug (IND) application with the Drug Controller General of India (DCGI) to conduct clinical phase-I study on its developmental candidate SUVN-502.
